D2-40、Ki-67、P53表达水平与结直肠癌淋巴结转移及术后辅助化疗后早期复发/转移的相关性研究OA
Correlation Study of Expression Levels of D2-40,Ki-67 and P53 with Lymph Node Metastasis and Early Recurrence/Metastasis After Postoperative Adjuvant Chemotherapy in Colorectal Cancer
目的:探讨结直肠癌(CRC)中D2-40、Ki-67及P53表达水平与CRC淋巴结转移及术后辅助化疗后早期复发/转移的相关性.方法:回顾性分析2021年3月至2025年3月我院就诊的205例CRC患者的临床资料,参考病理检查结果,将70例CRC淋巴结转移患者归入转移组,将135例未出现淋巴结转移患者纳入未转移组.采用免疫组化法检测术后病理组织中Ki-67、D2-40及P53表达水平,比较两组临床资料并分析CRC危险因素.根据Ki-67表达量分组,统计每组中淋巴结转移率,绘制ROC曲线,明确Ki-67、D2-40的最佳截断值及曲线下面积(AUC),分析上述指标单独检测与联合检测对CRC淋巴结转移的预测价值.CRC术后接受≥4周期FOLFOX或XELOX方案辅助化疗,半年后复查电子结肠镜及胸腹部CT,根据肿瘤临床复发情况,将符合条件的75例复查未见异常患者纳入无复发组,13例复发/转移患者纳入复发组,比较两组临床特征及D2-40、Ki-67、P53的表达差异.结果:CRC淋巴结转移与肿瘤分化程度、脉管内癌栓、肿瘤浸润深度和D2-40的表达相关(P<0.01),淋巴结转移组Ki-67的表达高于无淋巴结转移组(P<0.05),CRC淋巴结转移率随Ki-67表达量增大而增高,Ki-67预测淋巴结转移的ROC曲线面积为0.599(95%CI:0.518-0.681,P=0.02).Ki-67最佳临界值为75.0%,预测淋巴结转移的灵敏度为39.1%,特异度为77.0%.术后追踪半年发现Ki-67表达低者CRC术后更容易出现早期临床复发/转移(P<0.05).结论:CRC术后检测Ki-67可对淋巴结转移进行预测,当Ki-67表达比例大于75.0%时很可能存在淋巴结转移,Ki-67也可能是观察CRC治疗后早期临床复发/转移的潜在指标.
Objective To investigate the correlations of expression levels of D2-40,Ki-67 and P53 with lymph node metastasis and early recurrence/metastasis after postoperative adjuvant chemotherapy in colorectal cancer(CRC).Methods Clinical data of 205 patients with CRC treated in our hospital from March 2021 to March 2025 were retrospectively analyzed.According to pathological findings,total 70 CRC patients with lymph node metastasis were assigned to the metastasis group,and 135 patients without lymph node metastasis to the non-metastasis group.Immunohistochemistry was applied to detect the expression levels of D2-40,Ki-67 and P53 in postoperative pathological tissues.Clinical data were compared between the two groups,and risk factors for CRC were analyzed.Patients were stratified by expression level of Ki-67,and the lymph node metas-tasis rate of each subgroup was calculated.Receiver operating characteristic(ROC)curves were plotted to determine the optimal cut-off values and area under the curve(AUC)of Ki-67 and D2-40,and the predictive values of single and combined detection of the above biomarkers for lymph node metastasis of CRC were ana-lyzed.All CRC patients received at least 4 cycles of adjuvant chemotherapy with FOLFOX or XELOX regi-mens.Electronic colonoscopy and thoracoabdominal CT reexamination were performed half a year after sur-gery.Based on tumor recurrence status,75 patients without abnormal imaging findings were included in the non-recurrence group,and 13 patients with recurrence/metastasis in the recurrence group.Clinical characteris-tics and differential expression of D2-40,Ki-67 and P53 were compared between the two groups.Results Lymph node metastasis of CRC was correlated with tumor differentiation,vascular tumor thrombus,depth of tumor invasion and D2-40 expression(P<0.01).Ki-67 expression was significantly higher in the lymph node metastasis group than in the non-metastasis group(P<0.05).The lymph node metastasis rate of CRC rose with the increase of Ki-67 expression.The AUC of Ki-67 for predicting lymph node metastasis was 0.599(95%CI:0.518-0.681,P=0.02).The optimal cut-off value of Ki-67 was 75.0%,with a sensitivity of 39.1%and specificity of 77.0%for predicting lymph node metastasis.Half-year postoperative follow-up revealed that patients with low Ki-67 expression were more prone to early recurrence/metastasis after CRC sur-gery(P<0.05).Conclusion Postoperative Ki-67 detection can predict lymph node metastasis in CRC.Lymph node metastasis is highly likely when the expression ratio of Ki-67 exceeds 75%.Ki-67 may also serve as a potential biomarker for monitoring early clinical recurrence/metastasis after CRC treatment.
李伯伟;叶金峰;洪锦伏;胡业茂;李蕊慧;叶家成;陈计胜;刘达宇
广东省阳江市人民医院肛肠外科(广东 阳江 529500)广东省阳江市人民医院肛肠外科(广东 阳江 529500)广东省阳江市人民医院肛肠外科(广东 阳江 529500)广东省阳江市人民医院肛肠外科(广东 阳江 529500)广东省阳江市人民医院肛肠外科(广东 阳江 529500)广东省阳江市人民医院肛肠外科(广东 阳江 529500)广东省阳江市人民医院肛肠外科(广东 阳江 529500)广东省阳江市人民医院肛肠外科(广东 阳江 529500)
结直肠癌淋巴结转移辅助化疗Ki-67D2-40P53疗效
Colorectal cancerLymph node metastasisAdjuvant chemotherapyKi-67D2-40P53Clinical efficacy
《中国肛肠病杂志》 2026 (6)
1-5,5
阳江市卫生健康局科技计划项目(202504)
评论